Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Therapeutic Drug Carrier Systems
Impact-faktor: 2.9 5-jähriger Impact-Faktor: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Druckformat: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v16.i1.10
83 pages

Formulation, Stability, and Delivery of Live Attenuated Vaccines for Human Use

Carl J. Burke
Department of Vaccine Pharmaceutical Research, Merck Research Laboratories, WP78-302, West Point, PA 19486 USA
Tsu-An Hsu
National Health Research Institutes, Taipei, Taiwan
David B. Volkin
Department of Vaccine Pharmaceutical Research, Merck Research Laboratories, WP78-302, West Point, PA 19486 USA

ABSTRAKT

The successful use of live attenuated viral and bacterial vaccines depends not only on the proper choice and delivery of the microorganisms, but also on maintaining the sufficient potency required for an immune response. The inherent lability of live organisms presents a particular formulation challenge in terms of stabilizing and preserving vaccine viability during manufacturing, storage, and administration. This review examines pharmaceutical approaches to the stabilization, formulation, and lyophilization of biological macromolecules in general, as well as the specific applicability of these principles to live attenuated viral and bacterial vaccines. Several formulation development case studies with live vaccines are presented. In addition, comparative stability data are summarized for many other live viral and bacterial preparations. Various pharmaceutical issues with conventional and novel delivery systems for administration of parenteral and oral live vaccines are also discussed.